{"id":8865,"date":"2004-11-06T02:57:56","date_gmt":"2004-11-06T02:57:56","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=8865"},"modified":"2014-05-22T16:35:16","modified_gmt":"2014-05-22T16:35:16","slug":"predictive-factors-of-virologic-success-in-hiv-positive-children-treated-with-lopinavirritonavir","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/8865","title":{"rendered":"Predictive factors of virologic success in HIV positive children treated with lopinavir\/ritonavir"},"content":{"rendered":"<p><strong>HIVandHepatitis.com<\/strong><\/p>\n<p><strong>Predictive factors of the virologic success of the use of the protease inhibitor lopinavir\/r (Kaletra) in HIV-infected children are unknown, especially in children who have been pretreated with protease inhibitors (PIs).<\/strong><\/p>\n<p>This longitudinal, single-centre, observational study included 69 children (21 PI-naive and 48 PI-experienced) who had received LPV\/r for at least 3 months. The mean (+\/-SD) age was 10.3 +\/- 4.8 years, and the mean baseline of CD4+ T cell percentage and HIV-1 RNA was 14.9% +\/- 9.8% and 4.8 +\/- 1.05 log<sub>10<\/sub> copies\/mL, respectively.<\/p>\n<p>The mean duration of follow-up was 16.5 +\/- 8.3 months.<\/p>\n<p>At 6, 12, and 18 months, 52%, 57%, and 49% of all children, respectively, had a viral load less than 50 copies\/mL. The risk of virologic failure, defined as two consecutive viral loads greater than 1000 copies\/mL, was significantly higher when the children were previously treated with PIs and when the baseline LPV mutation score exceeded 3 mutations.<\/p>\n<p>In the pretreated children, the ratio of the plasma LPV maximal concentration to the baseline LPV score mutation was also associated with failure, independently of resistance score.<\/p>\n<p>Finally, in children failing an LPV-containing regimen, accumulation of additional PI-associated resistance mutations was evidenced in viral isolates from children with prior PI treatment, even with viral replication levels less than 10,000 copies\/mL.<\/p>\n<p>The authors conclude: \u201cIn pretreated children, LPV plasma levels should be optimised in an attempt to achieve sufficient drug concentrations to overcome the resistance level.\u201d<\/p>\n<p>Source: HIVandHepatitis.com<\/p>\n<p>\u00a9 Copyright 2004 by HIV and Hepatitis.com. All Rights Reserved. Reproduction for personal or educational use is encouraged and does not require permission. Written permission is required to re-print copyrighted articles but is almost always granted (email:\u00a0<a href=\"mailto:publisher@HIVandHepatitis.com\">publisher@HIVandHepatitis.com<\/a>).<\/p>\n<p>Reference:<\/p>\n<p>Delaugerre C et al. Predictive factors of virologic success in HIV-1-infected children treated with lopinavir\/ritonavir. Journal of Acquired Immune Deficiency Syndromes 37(2): 1269-1275. 1 October 2004.<br \/>\n<a href=\"http:\/\/www.hivandhepatitis.com\/recent\/children\/100404_a.html\">http:\/\/www.hivandhepatitis.com\/recent\/children\/100404_a.html<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>HIVandHepatitis.com Predictive factors of the virologic success of the use of the protease inhibitor lopinavir\/r (Kaletra) in HIV-infected children are unknown, especially in children who have been pretreated with protease inhibitors (PIs). This longitudinal, single-centre, observational study included 69 children &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[32],"tags":[],"class_list":["post-8865","post","type-post","status-publish","format-standard","hentry","category-paediatric-care"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/8865","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=8865"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/8865\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=8865"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=8865"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=8865"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}